FDA Approves Clinical Trial Using Mesenchymal Stem Cells Idiopathic Pulmonary Fibrosis

mesenchymal stem cell

 

 

 

 

 

 

 

 

Researchers at University of Miami Health System receive FDA approval for the first U.S. clinical trial using mesenchymal stem cells to treat idiopathic pulmonary fibrosis. Mesenchymal stem cells are multipotent adult stem cells that can be isolated from bone marrow, teeth, and fat.  Mesenchymal stem cells have demonstrated the ability to differentiate into bone, cartilage, cardiomyocites, muscle, neuronal cells, insulin producing pancreatic beta cells and more.

Continue reading